The evidence for GLP-1 medications in treating NASH (the more severe form of fatty liver disease) is particularly impressive: Liraglutide achieved histological resolution of steatohepatitis in 39% of cases after 48 weeks, compared to just 9% in placebo groups 20 Patients taking liraglutide had 4.5 times higher likelihood of NASH resolution than those on placebo 20 Semaglutide demonstrated NASH resolution in 59% of participants versus 17% in placebo groups 21 We offer FibroScan technology to measure liver stiffness and fat content, helping us monitor your progress while on GLP-1 therapy
They may suggest adjusting the dose, slowing the titration schedule, or prescribing anti-nausea medication to help you stay on track with treatment
Sulfonylureas Sulfonylureas, commonly prescribed for managing Type 2 diabetes, can interact with GLP-1 receptor agonists, requiring careful monitoring
For some, a daily routine is easier to sustain than a weekly one
In the event of an immediate adverse reaction during intravenous infusion, the administration of the drug should be interrupted immediately and, if possible, the unused remaining liquid should be saved for examination
Miras AD, Prez-Pevida B, Aldhwayan M, Kamocka A, McGlone ER, Al-Najim W, et al